1.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 1 to under 22 at first relapse
Sponsor: NCI
Protocol IDs: COG-ASCT0431, ASCT0431, COG-PBMTC-ONCO51, NCT00382109
|
|
2.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ZSH-LCI-FJ-0002, NCT00554125
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 72
Sponsor: NCI, Other
Protocol IDs: 09-073, NCT00928018
|
|
4.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: COG-AAML1031, AAML1031, NCT01371981
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: 2011-0628, NCT01471444
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI, NHLBI
Protocol IDs: 715, 2U10HL069294-11, NCT01597778
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 55
Sponsor: NCI, Other
Protocol IDs: CDR0000525755, MSKCC-06125, NCT00423514
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2064.00, NCI-2010-00238, P01HL036444, FHCRC-2064.00, 6294, NCT00453388
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: NCI, NHLBI
Protocol IDs: 383, BMT CTN 0301, 5 U01 HL69294-05, FHCRC-2051.00, NCT00326417
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: EK 92062003, NCT00460447
|
|
11.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 69
Sponsor: NCI
Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: L 9471, NCT00529360
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 17 to 70
Sponsor: Other
Protocol IDs: 2067.00, NCI-2011-01352, R01AI041721, FHCRC-2067.00, 6364, NCT00622895
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776
|
|
16.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 montha to 70
Sponsor: Other
Protocol IDs: J1055, NA_00039823, NCT01203722
|
|
17.
|
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 1012-24; IUCRO-0307, NCT01303965
|
|
18.
|
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 6 months to 85
Sponsor: Other
Protocol IDs: J1151, NA_00048378, NCT01342289
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: AMCPHO-SCT0902, NCT01509300
|
|
20.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2012-0249, NCT01629511
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: 2012-0265, NCT01664910
|
|
22.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: Under 75
Sponsor: NCI, Other
Protocol IDs: 1898.00, NCI-2010-00267, P01HL036444, P01CA078902, FHCRC-1898.00, 5788, NCT00089011
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 50 to 70
Sponsor: Other
Protocol IDs: RMBMT-124-A, NCT00304720
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 10 to 75
Sponsor: NHLBI
Protocol IDs: NHLBI-06-H-0248, NHLBI-IDE-13058, NCT00398346
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 65
Sponsor: Other
Protocol IDs: 2005-0015, NCT00385788
|
Mobile | Español
